María Luisa Limón

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

Thierry André, Elena Élez, Eric Van Cutsem et al. · New England Journal of Medicine · 2024 · 158 citations

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer

Joan Albanell, Antonio González, Manuel Ruíz‐Borrego et al. · Annals of Oncology · 2011 · 120 citations · Full text

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

Thierry André, Elena Élez, Heinz‐Josef Lenz et al. · The Lancet · 2025 · 115 citations

Medicine, Colorectal Cancer, Pathology +6

Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)

Heinz‐Josef Lenz, Eric Van Cutsem, María Luisa Limón et al. · Annals of Oncology · 2018 · 92 citations · Full text

Low-dose Ipilimumab, Medicine, Immunology +8

MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer

Sonia Molina‐Pinelo, Amancio Carnero, Fernando Rivera et al. · BMC Cancer · 2014 · 75 citations · Full text